PPT-CD19-directed CAR T-cell therapy is feasible for older patients in the outpatient setting
Author : layla | Published Date : 2023-05-20
Andrew Ly Khaled Sanber HuaLing Tsai Angela Ondo Kathy Mooney Audra Shedeck Philip H Imus Nina WagnerJohnston Tania Jain Presented by Andrew Ly M2 Introduction
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "CD19-directed CAR T-cell therapy is feas..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
CD19-directed CAR T-cell therapy is feasible for older patients in the outpatient setting: Transcript
Andrew Ly Khaled Sanber HuaLing Tsai Angela Ondo Kathy Mooney Audra Shedeck Philip H Imus Nina WagnerJohnston Tania Jain Presented by Andrew Ly M2 Introduction to CAR Tcells. Stuart S. Winter, MD. Pediatric Hematology/Oncology. The T. John Gribble Endowed Chair. Background- Acute Lymphoblastic Leukemia in Children & Young Adults. Risk Classification Strategy. Through improved approaches to risk classification, therapy intensification, and supportive care, children and young adults with acute lymphoblastic leukemia (ALL) have an overall survival rate that currently exceeds 80%. Sa . A.Wang. 1. Theodore Laetsch. 2. “Buddy” Frank Fuda. 2 . and. Sindhu Cherian. 3. 1 MD Anderson Cancer Center; 2 University of Texas Southwestern Medical Center; 3 University of Washington Medical Center. Sa . A.Wang. 1. Theodore Laetsch. 2. “Buddy” Frank Fuda. 2 . and. Sindhu Cherian. 3. 1 MD Anderson Cancer Center; 2 University of Texas Southwestern Medical Center; 3 University of Washington Medical Center. with . Acceptable Toxicity . but . w. ithout . Chronic B-Cell Aplasia . in . Children . with . Relapsed . or . Refractory Acute Lymphoblastic Leukemia (ALL) Even . After . Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) . . Gabrielle . Gaultier, . PhD Biotechnology . Candidate . Lakehead. University . Supervisor: Dr. Marina Ulanova . Northern Health Research Conference 2017. 1. Faculty/ Presenter Disclosure Slide. 2. nhl. Presenting by . F.Malek. M.D. Assistant Professor Ped Hematologist & Oncologist . Mofid. Children’s Hospital. Introduction. The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. . 285 Review Article 286 lymphocytes (TILs) in combination with lymphodepletion for the treatment of advanced melanoma. However, DLI is usually associated with life-threatening forms of GVHD, and ith un Alfred Fisher MD PhD. Associate Professor and Chief. Division of Geriatrics, Gerontology, and Palliative Medicine. Department of Internal Medicine. University of Nebraska Medical Center. Al. ё. na A. Balasanova, M.D., FAPA. Stem Cell Transplant for . Primary . Immunodeficiencies. Nancy Bunin, MD. Medical Director. , . Cell Therapy and Transplant . Program. Division of Oncology. To DISCUSS. SCID . Newborn Screening. Transplant controversies. Alfred Fisher MD PhD. Professor and Chief. Division of Geriatrics, Gerontology, and Palliative Medicine. Department of Internal Medicine. University of Nebraska Medical Center. Al. ё. na A. Balasanova, M.D., FAPA. Leanage. Marker. Leucocyte. CD45+. Total T cell. CD45+. CD3+. CD4+ T cell. CD45+. CD3+. CD4+. CD8+ T cell. CD45+. CD3+. CD8+. B cell. CD45+. CD3-. CD19+. Monocyte / Macrophage. CD45+. CD3-. CD19-. CD14+. Blood bank rotation presentation. 9/20/18. Outline. Mechanism of CAR T cell therapy. Manufacturing process. Challenges . of expanding CAR T cell therapy to a . larger . patient population. . world-wide. Diffuse Large B Cell Lymphoma. Foroud. . shahbazi. . Pharm.D. Introduction . Diffuse large B cell lymphoma (DLBCL) is the most common form . of aggressive . NHL accounting for approximately 30%-40% of cases. 03.02.2022. Geriatric screening in older adults with cancer using electronical patient-reported outcome measures (PROMs) . - a feasible approach in a resource limited setting. NORDIC9-study – an . update.
Download Document
Here is the link to download the presentation.
"CD19-directed CAR T-cell therapy is feasible for older patients in the outpatient setting"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
